The authors found that tirzepatide 15mg was the most efficacious in reducing HbA1c versus placebo (mean difference -2.00%), followed by tirzepatide 10mg (-1.86%) and semaglutide 2.0mg (-1.62%)
Consequently, this meta-analysis provides a more rigorous and clinically relevant evaluation of the relative therapeutic benefits of Semaglutide, Liraglutide, Dulaglutide, and Tirzepatide, facilitating a more evidence-based approach to treatment selection in the management of type 2 diabetes and obesity
Serious risks & who should not take it Serious but less common risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and low blood sugar (especially if combined with insulin or sulfonylureas)
The powder form should be protected from moisture and extreme temperatures, with proper packaging ensuring 24-month shelf life under appropriate storage conditions